A Grayev1, M Schoepp2, A Kuner2. 1. From the School of Medicine and Public Health, University of Wisconsin, Madison, WisconsinFrom the School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin. agrayev@uwhealth.org. 2. From the School of Medicine and Public Health, University of Wisconsin, Madison, WisconsinFrom the School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin.
Abstract
BACKGROUND: Spinal muscular atrophy is a progressive neurodegenerative disorder that can be treated with intrathecal antisense oligonucleotide therapy (nusinersen). However, administration is often complicated by posterior spinal fusion and neuromuscular scoliosis, necessitating a transforaminal approach. PURPOSE: To assess the safety profile of the transforaminal approach for intrathecal access. DATA SOURCES: Searches of the PubMed, Web of Science, and SCOPUS databases. STUDY SELECTION: Thirteen articles were selected based on inclusion of transforaminal access and appropriate clinical information about the procedure. DATA ANALYSIS: Complications were taken from the included articles and aggregated based on Cardiovascular and Interventional Radiological Society of Europe scale adverse event grading. DATA SYNTHESIS: Total number of complications and grade of complications were analyzed, by year and in total. LIMITATIONS: Selection bias in publication, small patient population size, and variability of the procedure limits the available data. CONCLUSIONS: Transforaminal approach is a safe alternative for intrathecal access in patients with spinal muscular atrophy and may be applicable to a larger patient population.
BACKGROUND: Spinal muscular atrophy is a progressive neurodegenerative disorder that can be treated with intrathecal antisense oligonucleotide therapy (nusinersen). However, administration is often complicated by posterior spinal fusion and neuromuscular scoliosis, necessitating a transforaminal approach. PURPOSE: To assess the safety profile of the transforaminal approach for intrathecal access. DATA SOURCES: Searches of the PubMed, Web of Science, and SCOPUS databases. STUDY SELECTION: Thirteen articles were selected based on inclusion of transforaminal access and appropriate clinical information about the procedure. DATA ANALYSIS: Complications were taken from the included articles and aggregated based on Cardiovascular and Interventional Radiological Society of Europe scale adverse event grading. DATA SYNTHESIS: Total number of complications and grade of complications were analyzed, by year and in total. LIMITATIONS: Selection bias in publication, small patient population size, and variability of the procedure limits the available data. CONCLUSIONS: Transforaminal approach is a safe alternative for intrathecal access in patients with spinal muscular atrophy and may be applicable to a larger patient population.
Authors: S Spiliopoulos; L Reppas; C Zompola; L Palaiodimou; M Papadopoulou; D Filippiadis; K Palialexis; A Ploussi; E Efstathopoulos; G Tsivgoulis; E Brountzos Journal: Eur J Neurol Date: 2020-04-28 Impact factor: 6.089
Authors: Mohammad A Mousa; David J Aria; Carrie M Schaefer; Robin D Kaye; Todd A Abruzzo; Saunder M Bernes; Scott D Willard; Monique C Riemann; Richard B Towbin Journal: Pediatr Radiol Date: 2018-07-18